Satoshi Ogiso
Overview
Explore the profile of Satoshi Ogiso including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
108
Citations
842
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ito T, Taura K, Fukumitsu K, Okumura S, Ogiso S, Anazawa T, et al.
J Hepatobiliary Pancreat Sci
. 2025 Feb;
PMID: 39996522
Background: The prognosis for unresectable perihilar cholangiocarcinoma (phCCA) is extremely poor. Liver transplantation in combination with neoadjuvant chemoradiation therapy has become the treatment of choice for unresectable phCCA in the...
2.
Ishii T, Yoh T, Nishio T, Nishino H, Kojima H, Ogiso S, et al.
Gan To Kagaku Ryoho
. 2025 Feb;
52(1):25-29.
PMID: 39957219
Conversion surgery means surgery for initially unresectable tumors which are converted to resectable tumors by multidisciplinary treatment. Since the introduction of highly effective drug therapies including immune checkpoint inhibitors for...
3.
Kanda S, Nishino H, Nishio T, Awidah T, Chikamori K, Yoh T, et al.
Ann Surg Oncol
. 2025 Feb;
32(4):2485-2486.
PMID: 39900715
No abstract available.
4.
Yamane K, Anazawa T, Nagai K, Kasai Y, Masui T, Izuwa A, et al.
Ann Surg Oncol
. 2025 Feb;
PMID: 39893341
Background: The efficacy of neoadjuvant chemoradiotherapy for resectable pancreatic ductal adenocarcinoma (R-PDAC) remains unclear. This study was designed to evaluate neoadjuvant chemoradiotherapy by using intensity-modulated radiotherapy (NAC-IMRT) for R-PDAC compared...
5.
Li X, Yoh T, Shimada K, Hori Y, Koyama Y, Ogiso S, et al.
World J Surg
. 2025 Jan;
49(3):708-716.
PMID: 39777692
Background: This study aimed to evaluate the outcomes and role of lymphadenectomy in hypervascular intrahepatic cholangiocarcinoma (ICC) quantified using the arterial phase of contrast-enhanced computed tomography (CT). Methods: Consecutive patients...
6.
Kanda S, Nishino H, Nishio T, Awidah T, Chikamori K, Yoh T, et al.
Ann Surg Oncol
. 2024 Dec;
32(4):2479-2480.
PMID: 39725749
Background: Techniques involving dye injection or regional ischemia are commonly used for the precise identification of liver regions during hepatectomy. The visualization of regions with indocyanine green (ICG) has been...
7.
Karasuyama T, Ishii T, Yoh T, Ogiso S, Takeda H, Takai A, et al.
Ann Surg Oncol
. 2024 Dec;
32(3):1819-1820.
PMID: 39671164
Background: Hepatocellular carcinoma (HCC) with inferior vena cava (IVC) tumor thrombus is generally considered to be borderline resectable because of its poor prognosis. This report describes a patient who underwent...
8.
Karasuyama T, Ishii T, Yoh T, Ogiso S, Takeda H, Takai A, et al.
Ann Surg Oncol
. 2024 Dec;
32(3):1837-1838.
PMID: 39666190
No abstract available.
9.
Fukumitsu K, Kageyama S, Ito T, Oimoto N, Ogiso S, Anazawa T, et al.
BMJ Open
. 2024 Nov;
14(11):e088188.
PMID: 39566949
Introduction: The only treatment for non-resectable colorectal liver metastasis (CRLM) is medical therapy, and the overall survival (OS) rate at 3 and 5 years is approximately 30%-40% and less than...
10.
Horie H, Oshima Y, Fukumitsu K, Iwaki K, Munekage F, Makino K, et al.
Tissue Eng Part A
. 2024 Sep;
PMID: 39276095
A bioengineered liver has the potential to save patients with end-stage liver disease, and a three-dimensional decellularized scaffold is a promising approach for practical use. The main challenge in bioengineered...